10/28/05:
The Economy Thrives Despite Hurricanes Rita & Katrina
SUSIE GHARIB: . The U.S. economy is surprisingly resilient
and stocks rallied today on the fresh economic data. The Dow
surged 172 points and the NASDAQ rose 26 on news that the
gross domestic product grew by a stronger than expected 3.8
percent in the third quarter. But as Suzanne Pratt reports,
there is concern about growth in the fourth quarter.
SUZANNE PRATT, NIGHTLY BUSINESS REPORT CORRESPONDENT: Despite
significant headwinds from both Katrina and Rita, U.S. economic
growth still accelerated quite nicely in the third quarter.
According to preliminary government data, GDP grew at annual
rate of 3.8 percent in the July through September period,
stronger than expected. GDP grew at a rate of 3.3 percent
in the second quarter and 3.8 percent in the first. Experts
credit strong consumer and government spending for the economy`s
resiliency
in the most recent quarter.
LAKSHMAN ACHUTHAN, MNG DIR, ECONOMIC CYCLE RESEARCH INST:
It`s the
whole package of the economy, including consumers, that is
more resilient than people were expecting. I think without
the impact of Katrina, you would have seen a number well above
4 percent, which is very different from what perceptions were
in the marketplace.
PRATT: High energy prices helped push up some of the headline
inflation gauges in the report. But core inflation data, which
strips out volatile food and energy costs, was well behaved.
Nevertheless, most economists believe the Federal Reserve
will continue hiking short-term interest rates at a modest
pace. Fed policymakers are widely expected to raise the Federal
funds rate to 4 percent when they meet on Tuesday.
ETHAN HARRIS, CHIEF U.S. ECONOMIST, LEHMAN BROTHERS: I think
it confirms to the Fed that they need to keep hiking interest
rates because you have an economy that seems to continue to
grow strongly despite every obstacle.
PRATT: While there is agreement on future Fed activity, there
is less unanimity on the outlook for economic growth. Some
experts say this latest GDP report suggests strong momentum
into the fourth quarter, while others expect the consumer
to ring fewer cash registers in the months ahead.
ACHUTHAN: I would be surprised if the fourth quarter saw
a strong acceleration from here, because we are likely to
see softer consumer spending during the holiday season as
a result of the higher energy costs taking away from the ability
to make discretionary purchases.
PRATT: In the coming months, the government will revise its
third quarter GDP report twice. And because of missing inventory
data for September, most economists expect the next reading
will be revised even higher. Suzanne Pratt, NIGHTLY BUSINESS
REPORT, New York.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright
(c) 2005 Community Television Foundation of South Florida,
Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05:
One On One With Peter Dolan, CEO, Bristol Myers Squibb
SUSIE GHARIB: Shares of Bristol Myers Squibb fell 2 1/2
percent today, as the drug maker reported quarterly earnings
that missed analyst estimates by $0.02 a share. The company
also lowered guidance for the year and said it might abandon
development of a key drug. In my exclusive interview with
Bristol Myers CEO Peter Dolan earlier today, I asked him if
things look better for 2006.
PETER DOLAN, CEO, BRISTOL MYERS SQUIBB: We`ll still experience
exclusivity losses in 2006 on one of our most important drugs
that is in our portfolio today, Pravachol. We will lose exclusivity
in April of 2006 in the U.S. We haven`t provided specific
guidance on 2006 yet. We will do that sometime at the beginning
of the year after we put our plan together for the year. We
anticipate that we will still be under pressure in 2006 from
an earnings standpoint as we deal with the Pravachol exclusivity
loss.
GHARIB: Mr. Dolan, how are you going to go about to boost
sales and also to recover lost sales given that some of your
blockbuster drugs are coming off of patent protection?
DOLAN: With exclusivity losses being a sure thing, when you
lose patent protection, you lose a significant percentage
of the revenue in a very short period of time. What you need
to be doing is reinventing yourself through new product launches
and portfolio growth that offsets that. In the last three
years, we`ve had significant exclusivity losses, but we`ve
also had successful new products that we launched.
GHARIB: How is Bristol Myers reinventing itself? What is
your strategy?
DOLAN: Two-thirds of our future growth, we think, will come
from our own discovery efforts. As we move towards bringing
these new products to market, more and more of them are coming
from our own discovery efforts. We want to complement that
by licensing new products from other company`s technology
that we can add to our portfolio. From a strategy standpoint,
we are focusing on disease areas of significant unmet medical
need. We have about 10 of those that we have identified as
places we want to make investments.
GHARIB: It looks like Bristol Myers is going more towards
being a specialty oriented drug company. Is that because it
is just harder to come up with big blockbusters like in the
past?
DOLAN: It is becoming more challenging in the industry for
most companies to bring blockbuster new products to the market.
And in our particular case, we think the focus we have on
areas of significant unmet medical need really poses a potential
strategic advantage for us.
GHARIB: So then give us an update on your thinking about
your new diabetes drug. I thought that was going to be key
to your strategy. Now I understand you may be abandoning it.
What is the story there?
DOLAN: Pargluva received an approvable letter from the FDA,
approvable meaning with more information, more analysis, et
cetera, they would potentially consider the risk benefit profile
and whether the drug ought to be on the market. What we announced
last night on Pargluva is, as we looked at this and the kinds
of questions the FDA was asking, we
subsequently decided that the studies that we had ongoing
were not necessarily going to answer all the FDA questions.
And so we`re evaluating whether we can and should continue
to make investments in Pargluva.
GHARIB: How will this impact your strategy?
DOLAN: It is not really a change in strategy because we are
still going to stay focused on the 10 disease areas. What
it does is it, it changes how we think about making investments
in various parts of our portfolio.
GHARIB: Let`s talk a little bit about Plavix, your blood-thinning
drug, another one of your big blockbusters that did well in
the quarter but is getting challenged by the generics. And
I understand that you have a trial coming up in April. How
are preparations going for that? And do you expect a positive
outcome like Pfizer got with its Lipitor case?
DOLAN: We believe the Plavix patent is valid and that it
is infringed. We are working with our partner Sanafi (ph)
to defend it vigorously. And I don`t really have any predictions
about what the outcome might be.
GHARIB: Let`s talk a little bit about Bristol stock. It has
been struggling recently. And then today it has been down
sharply on your quarterly numbers. How committed is Bristol
to the dividend?
DOLAN: We have said we would continue to evaluate it. We
view it as a priority. With the exception of the loss of a
Plavix patent prematurely, which would be a major event which
would cause us to rethink our operational and financial priorities,
we would continue to make the dividend a priority.
GHARIB: Mr. Dolan, thank you so much.
DOLAN: OK, thank you, thank you, Susie.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2005 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05: Will The Libby Indictment
Rock The White House?
PAUL KANGAS: Vice President Cheney`s chief of staff, Lewis
Libby was indicted today on five criminal counts including
perjury, in the investigation of the leak of the identity
of a CIA agent. Libby resigned and has left the White House.
The indictment is the latest challenge in what has been a
challenging week for the Bush administration. But as
Stephanie Dhue reports, experts don`t think Libby`s problems
will derail the president`s agenda on Capitol Hill.
STEPHANIE DHUE, NIGHTLY BUSINESS REPORT CORRESPONDENT: Despite
the
indictment and continued investigation of his inner circle,
President Bush promised to keep on track with his economic
policy and naming a new Supreme Court nominee.
GEORGE W. BUSH, PRESIDENT OF THE UNITED STATES: While we`re
all saddened by today`s news, we remain wholly focused on
the many issues and opportunities facing this country. I`ve
got a job to do and so do the people who work in the White
House.
DHUE: The indictment caps a week of bad news for the Bush
administration. U.S. casualties in the Iraq war have now topped
2,000. Harriet Miers withdrew her Supreme Court nomination
under heavy criticism from conservatives. Consumer confidence
dropped and hurricane Wilma blew through south Florida. Analysts
who watch Washington from Wall Street say the Libby indictment
may not have much impact on the president`s already struggling
agenda.
JOE LIEBER, POLITICAL ANALYST: I view this as like a value
stock or a company who is going to have a negative earnings
in a quarter and they decide to throw all the negative news
in that quarter.
DHUE: But there may be more fallout from special counsel
Patrick Fitzgerald`s investigation as it moves toward a trial.
PATRICK FITZGERALD, JUSTICE DEPT. SPECIAL COUNSEL: The need
to get to the bottom of what happened, and whether national
security was compromised by inadvertence, by recklessness,
by maliciousness is extremely important and we need to know
the truth.
DHUE: It looks like any truth seeking will take place in
the court. Meanwhile the focus on Capitol Hill next week will
shift to two big items on the Bush agenda, the budget and
tax reform. Stephanie Dhue, NIGHTLY BUSINESS REPORT, Washington.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2005 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05: Market Monitor --
Donald Straszheim, President & CEO, Straszheim Global
Advisors
PAUL KANGAS: My guest market monitor this week is Donald
Straszheim, president and chief executive officer of Straszheim
Global Advisors, an independent research firm focusing on
the United States, China and the global economy. Welcome back
to NIGHTLY BUSINESS REPORT, Don!
DONALD STRASZHEIM, PRES & CEO, STRASZHEIM GLOBAL ADVISORS:
Paul, thank
you, nice to be with you again.
KANGAS: It`s my understanding that you have decided to close
down your advisory firm to pursue other interests. Give us
an update on what`s going on there.
STRASZHEIM: Well, Paul, the activity in China has been absolutely
frantic the last couple of years. And my own company has simply
consumed me, without any time, really, to think and write.
So we`ve decided to close the firm down and I`m in the process
now of writing a book so I`ve got something to do while I`m
thinking about what I do next and I`m on the bread line.
KANGAS: OK. As an acknowledged expert on China and one who
has defied the consensus and correctly predicted over a year
ago that China`s growth will not be slowing down to any extent,
do you see any change in that now?
STRASZHEIM: No. China`s economy is still growing about 9
percent a year. That is a sustainable pace for I think a long
time to come in China, the fastest in the world. And it provides
great investment opportunities for everybody, much more of
an opportunity for America than the threat.
KANGAS: All right. Now you were Merrill Lynch`s chief economist
for a dozen years. So using that expertise, tell us what is
happening to the U.S. economy and where is our stock market
headed?
STRASZHEIM: Well, we`ve still got this growth -- we just
reported this morning 3.8 percent, really quite solid. We`ve
had 10 or 12 quarters in a row now of growth over 3 percent.
I don`t see that ending in the next few quarters. We`ve got
some problems. The inflation rate is up a little bit. That
is an issue for the Fed in particular. Interest rates are
up. They are going to come up a little bit more. But earnings
are very solid and I think we`ll continue to have good growth
on into 2006.
KANGAS: What about the market, stock market?
STRASZHEIM: Well, I think the stock market, quite frankly,
is going to be very choppy, really kind of headed nowhere,
just like we`ve seen the last few months. Some big up days
and some big down days, a lot of volatility.
KANGAS: OK. Now on to your last visit with us in late April,
you gave us three buy recommendations. Let`s see how they
have done. The first one we see is the Hong Kong index shares,
the I shares and they are up 3.7 percent. You like those.
STRASZHEIM: Yes, I liked them then and still do right now.
That`s by the way the I shares in Hong Kong is the best way,
really, for people in America, and a lot of other places to
play China.
KANGAS: OK and Shanda Interactive, that was a real kind of
a doggie, down 22 percent.
STRASZHEIM: It has -- down sharply.
KANGAS: You`re out of it.
STRASZHEIM: Online games, out of it. Don`t want to get back
in.
KANGAS: OK. And you gave us one other, I believe last time
you were with us in late April and that was Yum Brands which
is up comfortably, 6.7 percent. Still like it?
STRASZHEIM: Exactly. Still like it. Do a great job in China,
easily the best fast food operator there and a great job here
as well.
KANGAS: OK, new recommendations Don.
STRASZHEIM: New recommendations is, first of all simply to
all simply to reiterate the I shares in Hong Kong. It`s a
cheap way to play a market. It`s very much suited to the individual
investor and Hong Kong is a big beneficiary of China.
KANGAS: OK. You still like them. All right. Let`s have another
choice. There we see Sinopec (ph).
STRASZHEIM: Exactly. Sinopec -- this is a refiner and processor
and marketer of oil and gasoline and gas products in China.
It`s kind of like an ExxonMobil. They are going to be a big
beneficiary of the ongoing growth and the reforms in China
allowing prices to rise.
KANGAS: We`re running out of time. We have time for one more
of your recommendations and we see ctrip.com.
STRASZHEIM: Ctrip, yes. That is an online and kind of normal
travel company, dominates the market and travel is going to
be a big deal in China for a long time to come.
KANGAS: OK, do you own personally any of these securities,
Don?
STRASZHEIM: No, don`t own any of them, no conflicts, like
to be objective and stay out of them.
KANGAS: Thanks very much for your observations, Don. Good
to see you again.
STRASZHEIM: Good, thanks, Paul, nice to see you too.
KANGAS: My guest Don Straszheim, author to be.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2005 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05: "Last Word"-- Halloween
Derails Orthodontia
SUSIE GHARIB: And finally tonight, if Halloween is one of
the best days of the year for kids, the day after Halloween
is one of the best for orthodontists. Every year, they say
that they get emergency calls from parents whose kids have
eaten too much chewy candy and messed up their braces. So
one orthodontist in Ohio has come up with a solution. Dr.
Kenneth Lawrence offers trick-or-treaters a dollar a pound
for their candy and then donates
it to charity. Last year, he gathered more than 80 pounds
of goodies. This year, Paul, he`s sending the candy to soldiers
serving in Iraq and he suspects most of it will end up in
the hands of Iraqi kids.
KANGAS: Well, I doubt whether many of them got braces under
the regime of Saddam Hussein.
GHARIB: You are probably right about that.
THE WEEK AHEAD
SUSIE GHARIB: Here`s a look at what`s happening for next week.
Our Friday market monitor guest is Douglas Jimerson, president
of National Investment Advisors. On the economic calendar:
Monday, September personal income and spending; Tuesday, the
Federal Reserve meets to decide what`s next for interest rates;
also on Tuesday, September construction spending and October
vehicle sales; Wednesday, weekly gas and oil inventories;
Thursday, September factory orders and third quarter productivity;
and then on Friday, the October employment report comes out.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2005 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05:
"Paul Kangas' Stocks In The News"
PAUL KANGAS: That robust third quarter GDP growth was just
what investors needed to breathe new life into Wall Street`s
moribund blue chips after three straight losing sessions.
A brokerage upgrade on Microsoft also helped the Dow climb
steadily to a 105 point gain at noontime, with the NASDAQ
up 18 points. The rally gained momentum with an upgrade on
Verizon, better than expected earnings from Avon and plenty
of short covering.
So the Dow industrial average vaulted 172.82 points to close
at 10,402.77 today. This week the Dow rose twice and fell
three times for a net gain of 187.55 points. The NASDAQ Composite
jumped 26 points closing at 2089.88 today. It also rose twice
and fell three times this week for an overall gain of 7.67.
The S&P 500 was up 19.5 points closing at 1198.41 today.
In the bond market, the 10-year note fell 4/32 to 97 16/32,
putting the yield at 4.57 percent.
Pfizer (PFE), a familiar name at the head of the active
list, 21.4 million shares topping it today. The stock up $0.40
a share.
ExxonMobil (XOM) gained $0.71.
Lucent (LU) a $0.04 gain.
Texas Instruments (TXN) rose $0.53.
And General Electric (GE), fifth in big board volume up $0.47.
A $0.02 loss in Ford Motor (F).
Verizon Communications (VZ) gained $0.94 after Merrill Lynch
upgraded it from "neutral" to "buy" on
the company`s improving outlook.
Citigroup (C) $0.49 gain.
Bristol Myers Squibb down $0.53. You just heard the interview
with the company CEO.
And Bank of America (BAC) an $0.80 gain, tenth in big board
volume.
Chevron (COP) the major oil, up $0.88. Big earnings, third
quarter $1.64, up from $1.51 last year, but that was believe
it or not, $0.21 below the Street consensus. Revenues were
however up 34 percent over last year.
Avon Products (AVP) did well, up $3.08. Third quarter earnings
a touch lower, $0.35 versus last year`s $0.37, but $0.06 above
the Street estimate. And Deutsche securities upgraded Avon
from "hold" to a "buy."
Metlife (MET) down $1.60 despite nicely higher third quarter
earnings of $0.97, up from $0.92 a year ago, $0.03 better
than the Street expected and revenues were up 20 percent,
but the stock`s had quite a run up.
International Rectifier (IRF) tumbling $6.19. Lower earnings
there, first quarter $0.41 versus $0.59 last year. Revenues
fell 13 percent. JPMorgan downgraded it from "overweight"
to just a "neutral" rating.
Mylan Labs (MYL) down $1.30. Second quarter earnings fell
to $0.16 from $0.18 a year ago. Revenues fell nearly 3 percent.
Terex (TEX) $1.92 gain there. Third quarter earnings jumped
$1.06 versus $0.89 last year. Revenues up 22 percent and the
construction equipment manufacturer also got a "buy"
rating from Standard & Poor`s, a good day for Terex.
Chemed Corporation (CHE), used to be called Roto Rooter,
third quarter earnings $0.55 up from $0.42 a year ago. Revenues
gained 16 percent over last year.
Brunswick (BC) up $2.85. Third quarter earnings rose to $0.89
from $0.75 a year ago. Revenues up 13 percent. Standard &
Poor`s repeated a "buy" on Brunswick.
Microsoft (MSFT) topped the active list moving up $0.68.
CS First Boston upgraded it from "neutral" to "out
perform" on yesterday`s better than expected earnings
and CS First Boston does have a $29 a share price target for
Microsoft stock.
Google (GOOG) a $5.11 gain there.
Qualcomm (QCOM) however, down $1.98. Several telecom companies
have filed complaints alleging Qualcomm is stifling competition
in the mobile phone chip market. Qualcomm says those allegations
are unfounded.
Apple Computer (AAPL) $0.94 loss there.
Intel (INTC) was fifth in dollar volume on NASDAQ and gained
$0.49.
Maxim Integrated (MXIM) plunging $4.36 a share. The company
had slightly higher earnings first quarter, $.39 versus $0.37,
in line with estimates, but Prudential Securities downgraded
the stock from "over weight" to just "neutral."
Cisco Systems (CSCO) $0.09 rise.
And Dell Computer (DELL) an $0.08 drop there.
Amgen (AMGN) up $2.23.
Tenth in dollar volume was Applied Materials (AMAT) with
a $0.35 loss.
Invitrogen (IVGN) a biochemical research firm plunging $9.02.
Third quarter earnings fell to $0.42 from $0.51 a year ago
and not only that, but the company cut its outlook, kind of
a rough day for Invitrogen.
We had a new issue today and that was Electro-Optical Sciences
(MELA), a company that makes medical devices. Four million
shares offered at $5. The stock opened at $6.60, got as high
as $8.50, fell back a bit, but still had a very good first
day of trading.
And those are the stocks in the news tonight.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2005 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
10/28/05:
Market Stats
NET PERCENT
CLOSE CHANGE CHANGE
DOW CLOSE 10402.77 +172.82 + 1.7
HIGH 10404.70
LOW 10231.15
NASDAQ COMP. 2089.88 +26.07 +1.3
HIGH 2089.88
LOW 2064.92
VOLUME 1,751.0
PREVIOUS 1,790.3
UP VOLUME 1,458.1
DOWN VOLUME 277.1
DOW TRANSPORTS 3741.81 +67.49 + 1.8
DOW UTILITIES 396.01 +8.98 + 2.3
CLOSING TICK +1134
S&P 500 1198.41 +19.51 + 1.7
S&P 100 554.48 +9.21 + 1.7
MIDCAP 400 689.51 +11.18 + 1.7
REUTERS/CRB 322.13 -1.28 - .4
NYSE COMPOSITE 7369.55 +106.23 + 1.5
VALUE LINE 389.23 +5.70 + 1.5
RUSSELL 2000 635.33 +11.30 + 1.8
DJW 5000 11947.36 +187.47 + 1.6
U.S. TREASURIES
5-YEAR NOTE 4.25%
Oct. 15,2010 99 3/32 -4/32 4.45
10-YEAR NOTE 4.25%
Aug. 15,2015 97 16/32 -4/32 4.57
30-YEAR NOTE 5.375%
Feb. 15, 2031 108 27/32 -2/32 4.77
LEHMAN BROS.
LONG BOND INDEX 1737.72 -.74
DOW CLOSE 10402.77 +172.82 + 1.7
ADVANCES 2408
DECLINES 871
NEW HIGHS 47
NEW LOWS 141
NET PERCENT
NYSE MOST ACTIVES 4PM CLOSE CHANGE CHANGE
PFE Pfizer 21.50 +.40 +1.9
XOM Exxon Mobil 56.31 +.71 +1.3
LU Lucent Tech 2.79 +.04 +1.5
TXN Texas Instrument 28.00 +.53 +1.9
GE GE 34.05 +.47 +1.4
F Ford Motor Co 8.02 -.02 -.3
VZ Verizon Comms 31.70 +.94 +3.1
C Citigroup 45.90 +.49 +1.1
BMY Bristol Myers Sq 21.14 -.53 -2.5
BAC Bank Of America 43.98 +.80 +1.9
NASDAQ CLOSE 2089.88 + 26.07 + 1.3
VOLUME 1,902.6
PREVIOUS 1,781.8
ADVANCES 2019
DECLINES 997
NASDAQ ACTIVES
MSFT Microsoft 25.53 +.68 +2.7
GOOG Google 358.17 +5.11 +1.5
QCOM Qualcomm 41.07 -1.98 -4.6
AAPL Apple Computer 54.47 -.94 -1.7
INTC Intel 23.33 +.49 +2.2
MXIM Maxim Integrated 34.60 -4.36 -11.2
CSCO Cisco Systems 17.14 +.09 +.5
DELL Dell 31.06 -.08 -.3
AMGN Amgen 75.78 +2.23 +3.0
AMAT Applied Matl 16.36 -.35 -2.1
AMEX CLOSE 1642.58 + 18.97 + 1.2
INDEX SHARES
DIA DIAMONDS TRUST 103.84 +1.50 +1.5
QQQ NASDAQ 100 38.32 +.29 +.8
SPY S&P DEP.RECEIPTS 119.84 +1.74 +1.5
STOCKS IN THE NEWS
CVX Chevron 57.38 +.88 +1.6
AVP Avon Products 27.79 +3.08 +12.5
MET MetLife 49.00 -1.60 -3.2
IRF Intl Rectifier 27.86 -6.19 -18.2
MYL Mylan Labs 20.30 -1.31 -6.1
TEX Terex 52.17 +1.92 +3.8
CHE Chemed 46.51 +6.23 +15.5
BC Brunswick 37.94 +2.85 +8.1
IVGN Invitrogen 61.76 -9.02 -12.7
MELA Electro-Optical 7.71 +2.71 +54.2
|
